Board/Management Information • Dec 19, 2023
Board/Management Information
Open in ViewerOpens in native device viewer
Date of report (Date of earliest event reported): December 18, 2023
(Exact name of registrant as specified in its charter)
| DELAWARE | 001-35813 | 98-0376008 | |
|---|---|---|---|
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer | |
| of Incorporation) | Identification No.) | ||
| 1185 Avenue of the Americas, Third Floor, New York, New York | 10036 | ||
| (Address of Principal Executive Offices) | (Zip Code) |
844-967-2633
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Name of each exchange on which | ||
|---|---|---|
| Title of each class | Trading symbol | registered |
| Common Stock, par value \$0.012 | ORMP | The Nasdaq Capital Market, |
| Tel Aviv Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On December 18, 2023, Oramed Pharmaceuticals Inc. (the "Company") increased the size of its Board of Directors (the "Board") by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.
The Board has not yet taken action to appoint Dr. Aghion to any committees of the Board.
Dr. Daniel Aghion, age 42, is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor's of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.
As remuneration for his service as a director, Dr. Aghion will receive the same fees as the Company's other non-executive directors. Except as otherwise set forth herein, there is no arrangement or understanding between Dr. Aghion and any other person pursuant to which he was elected as a director, and there are no transactions in which Dr. Aghion has an interest requiring disclosure under Item 404(a) of Regulation S-K. In connection with Dr. Aghion's appointment, the Company expects to enter into its standard indemnification agreement with Dr. Aghion, on substantially the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By: /s/ Nadav Kidron
Name: Nadav Kidron Title: President and CEO
December 18, 2023
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.